title: Leukaemia inhibitory factor receptor and gp130 in the human Fallopian tube and endometrium before and after mifepristone treatment and in the human preimplantation embryo.
abstract: Leukaemia inhibitory factor (LIF) is a cytokine, which is associated with reproductive processes such as embryo development and implantation. The objectives of this study were to detect the presence of LIF receptor (LIFR) and glycoprotein 130 (gp 130) in the human Fallopian tube, endometrium and preimplantation embryo and to study the effect of mifepristone on the expression of LIFR and gp130 in the Fallopian tube. Twenty-two healthy fertile women received a single dose of 200 mg mifepristone or placebo immediately after ovulation (LH + 2). Biopsies were obtained from the Fallopian tubes during laparoscopic sterilization once between days LH + 4 and LH + 6 and from endometrium once between days LH + 6 and LH + 8. Preimplantation embryos were received from couples undergoing in vitro fertilization treatment. Immunohistochemistry was used to detect the presence of LIFR and gp130 in the Fallopian tube, endometrium and preimplantation embryo. Real-time PCR was used to study LIFR and gp130 expression in the Fallopian tube and endometrium. LIFR and gp130 were localized in the Fallopian tube, preimplantation embryo and endometrium. LIFR was more abundant in the Fallopian tube than in the endometrium. In the blastocyst, the staining of gp130 was mainly localized in the inner cell mass, whereas LIFR was expressed in all cells. The presence of LIFR and gp130 in the Fallopian tube and preimplantation embryo indicates a role for LIF in communication between the embryo and the Fallopian tube. Mifepristone did not affect the expression of LIFR and gp130 in the Fallopian tube, nor in the endometrium suggesting that progesterone might not be directly involved in the regulation of LIFR or gp130.
authors: Department of Woman and Child Health, Division of Obstetrics and Gynaecology, Karolinska Institutet, Karolinska University Hospital, S-171 76 Stockholm, Sweden. kjell.wanggren@karolinska.se
authors: K
authors: K
authors: Wånggren
authors: P G
authors: PG
authors: Lalitkumar
authors: F
authors: F
authors: Hambiliki
authors: B
authors: B
authors: Ståbi
authors: K
authors: K
authors: Gemzell-Danielsson
authors: A
authors: A
authors: Stavreus-Evers
mesh_terms: D000328:Adult; D001755:Blastocyst / Q000187:drug effects / Q000378:metabolism*; D050822:Cytokine Receptor gp130 / Q000378:metabolism*; D004717:Endometrium / Q000378:metabolism*; D005187:Fallopian Tubes / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit / Q000378:metabolism*; D015735:Mifepristone / Q000494:pharmacology*
chemical_list: D006727:Hormone Antagonists; C507840:LIFR protein, human; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D050822:Cytokine Receptor gp130; D015735:Mifepristone